SCORE Search Results Details for Application 10552515 and Search Result 20080630 144055 us-10-552-515-7.rag.

This page gives you Search Results detail for the Application 10552515 and Search Result 20080630_144055_us-10-552-515-7.rag.

```
                          GenCore version 6.2.1
               Copyright (c) 1993 - 2008  Biocceleration Ltd.


OM protein - protein search, using sw model

Run on:            June 30, 2008, 17:43:01 ; Search time 71 Seconds
                                             (without alignments)
                                             76.429 Million cell updates/sec

Title:             US-10-552-515-7
Perfect score:     40
Sequence:          1 ILILSKIYV 9

Scoring table:     BLOSUM62
                   Gapop 10.0 , Gapext 0.5

Searched:          3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters:      3405708

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :         A_Geneseq_200711:*
                   1:  geneseqp1980s:*
                   2:  geneseqp1990s:*
                   3:  geneseqp2000:*
                   4:  geneseqp2001:*
                   5:  geneseqp2002:*
                   6:  geneseqp2003a:*
                   7:  geneseqp2003b:*
                   8:  geneseqp2004a:*
```

```
 9:  geneseqp2004b:*
10:  geneseqp2005:*
11:  geneseqp2006:*
12:  geneseqp2007:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	40	100.0	9	8	ADT77670	Adt77670 Splice va
2	40	100.0	843	10	AEB13424	Aeb13424 Human pro
3	40	100.0	885	10	AEB13426	Aeb13426 Human pro
4	40	100.0	898	4	ABG15488	Abg15488 Novel hum
5	40	100.0	933	8	ADT77664	Adt77664 Splice va
6	40	100.0	933	11	AEL84788	Ael84788 Tumor mar
7	33	82.5	67	8	AFP84242	Afp84242 Glycine m
8	32	80.0	84	12	AER37498	Aer37498 Human sec
9	32	80.0	117	5	ABB53430	Abb53430 Lactococc
10	32	80.0	199	4	AAU19199	Aau19199 Human G p
11	32	80.0	293	4	ABG29976	Abg29976 Novel hum
12	32	80.0	366	8	AET18366	Aet18366 C. albica
13	32	80.0	596	8	ADR09066	Adr09066 Human pro
14	32	80.0	726	8	ADR09060	Adr09060 Human pro
15	32	80.0	766	8	ADR09928	Adr09928 Human pro
16	32	80.0	955	7	AEE72788	Aee72788 Novel hum
17	32	80.0	1329	4	ABG16666	Abg16666 Novel hum
18	32	80.0	1329	6	ADC33203	Adc33203 Human nov
19	31	77.5	25	10	ADV76906	Adv76906 Human CYP
20	31	77.5	53	8	ADS05816	Ads05816 Staphyloc
21	31	77.5	53	11	AEI11899	Aei11899 Staphyloc
22	31	77.5	101	8	AFP93181	Afp93181 Glycine m
23	31	77.5	103	8	AFQ94206	Afq94206 Glycine m
24	31	77.5	184	8	AET15710	Aet15710 C. albica
25	31	77.5	250	6	ADI21708	Adi21708 Novel hum
26	31	77.5	289	8	ADN24582	Adn24582 Bacterial
27	31	77.5	312	8	ADN21823	Adn21823 Bacterial
28	31	77.5	333	11	AFC43045	Afc43045 Soybean a
29	31	77.5	334	11	AFC43044	Afc43044 Soybean a
30	31	77.5	503	10	ADV76908	Adv76908 Human CYP
31	31	77.5	758	5	ABP35698	Abp35698 Fungal ZB
32	31	77.5	883	8	AET22003	Aet22003 C. albica
33	31	77.5	1014	8	ADR08763	Adr08763 Human pro
34	31	77.5	1063	6	ADI21257	Adi21257 Novel hum
35	31	77.5	1130	8	ADQ66163	Adq66163 Novel hum

```
        36       31      77.5    1147   8    ADL46160           Adl46160 Murine so
        37       31      77.5    1167   8    ADL46161           Adl46161 Murine so
        38       31      77.5    1168   6    ADC42845           Adc42845 REMAP pro
        39       31      77.5    1168   8    ADL46153           Adl46153 Human Sor
        40       31      77.5    1168   8    ADQ91462           Adq91462 Amino aci
        41       31      77.5    1168  10    AEP65139            Aep65139 Alzheimer
        42       31      77.5    1168  11    AGA32607            Aga32607 Alzheimer
        43       31      77.5    1178   8    ADL46162           Adl46162 Murine so
        44       31      77.5    1219   8    ADL46159           Adl46159 Murine so
        45       31      77.5    1222   8    ADL46151           Adl46151 Human Sor
```

ALIGNMENTS

RESULT 1
ADT77670
ID   ADT77670 standard; peptide; 9 AA.
XX
AC   ADT77670;
XX
DT   13-JAN-2005 (first entry)
XX
DE   Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.
XX
KW   Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW   prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.
XX
OS   Homo sapiens.
XX
PN   WO2004092213-A1.
XX
PD   28-OCT-2004.
XX
PF   05-APR-2004; 2004WO-US010588.
XX
PR   08-APR-2003; 2003US-0461399P.
XX
PA   (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Pastan I, Bera TK, Lee B;
XX
DR   WPI; 2004-758338/74.
XX
PT   New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT   encoding nucleic acid molecule for diagnosing, preventing or treating
PT   cancer, especially prostate cancer.
XX
PS   Disclosure; SEQ ID NO 7; 88pp; English.

```
XX
CC      The present sequence is that of a predicted epitope of human splice
CC      variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope
CC      is predicted to bind HLA2-01 and was identified using an HLA binding
CC      motif program. It corresponds to amino acids 557-565 of SV-NGEP.
CC      Polypeptides comprising an immunogenic fragment of 8 consecutive amino
CC      acids of SV-NGEP which specifically bind to an antibody that specifically
CC      binds a polypeptide comprising amino acids 157-933 of SV-NGEP are
CC      claimed. The invention provides methods for: detecting prostate cancer in
CC      a subject by contacting a sample with an antibody that specifically binds
CC      a SV-NGEP polypeptide and detecting the formation of an immune complex,
CC      or detecting an increase in expression of SV-NGEP polypeptide or mRNA;
CC      producing an immune response against a cell expressing SV-NGEP, for
CC      example in a subject with prostate cancer, by administering SV-NGEP
CC      polypeptide or polynucleotide to produce an immune response that
CC      decreases growth of the prostate cancer; inhibiting the growth of a
CC      malignant cell that expresses SV-NGEP by culturing cytotoxic T
CC      lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting
CC      these with the malignant cell; and inhibiting the growth of a malignant
CC      cell by contact with an antibody that specifically binds SV-NGEP, where
CC      the antibody is linked to a chemotherapeutic agent or toxin.
XX
SQ      Sequence 9 AA;

  Query Match             100.0%;  Score 40;  DB 8;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+06;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ILILSKIYV 9
              |||||||||
Db          1 ILILSKIYV 9


RESULT 2
AEB13424
ID   AEB13424 standard; protein; 843 AA.
XX
AC   AEB13424;
XX
DT   22-SEP-2005   (first entry)
XX
DE   Human prostate specific polypeptide #1.
XX
KW   Screening; diagnosis; drug delivery; prostate specific polypeptide;
KW   cancer; prostate tumor; cytostatic; neoplasm.
XX
OS   Homo sapiens.
XX
PN   WO2005062788-A2.
```

```
XX
PD    14-JUL-2005.
XX
PF    16-DEC-2004; 2004WO-US042406.
XX
PR    22-DEC-2003; 2003US-0531809P.
XX
PA    (AVAL-) AVALON PHARM INC.
XX
PI    Weigle B,  Ebner R;
XX
DR    WPI; 2005-497793/50.
DR    N-PSDB; AEB13423.
XX
PT    Novel isolated prostate specific polypeptide, useful for treating cancer,
PT    and identifying agent that modulates activity of cancer related gene.
XX
PS    Claim 12; SEQ ID NO 3; 59pp; English.
XX
CC    The invention relates to an isolated prostate specific polypeptide
CC    comprising one or more immunogenic fragments. The invention also relates
CC    to a method of identifying an agent that modulates the activity of a
CC    cancer related gene involving contacting a compound with a cell
CC    containing a gene under conditions promoting the expression of the gene,
CC    detecting a difference in expression of the gene relative to when the
CC    compound is not present and identifying an agent that modulates the
CC    activity of a cancer related gene, a method of identifying an anti-
CC    neoplastic agent involving contacting a cell exhibiting neoplastic
CC    activity with a compound first identified as a cancer related gene
CC    modulator using and determining a decrease in neoplastic activity after
CC    contacting, when compared to when the contacting does not occur, or
CC    administering an agent first identified to an animal exhibiting a cancer
CC    condition and detecting a decrease in cancerous condition, a method of
CC    determining the cancerous status of a cell involving determining an
CC    increase in the level of expression in a cell of a gene where an elevated
CC    expression relative to a known non-cancerous cell indicates a cancerous
CC    state or potentially cancerous state, an antibody that reacts with a
CC    prostate specific polypeptide, an immunoconjugate comprising the antibody
CC    a cytotoxic agent, a method of treating cancer involving contacting a
CC    cancerous cell in vivo with an agent having activity against a prostate
CC    specific polypeptide and an immunogenic composition the prostate specific
CC    polypeptide. The prostate specific polypeptide is useful for identifying
CC    an agent that modulates the activity of a cancer related gene. The
CC    immunogenic composition is useful for treating cancer, preferably
CC    prostate cancer in an animal, e.g. human, which involves administering
CC    the immunogenic composition that is sufficient to elicit the production
CC    of cytotoxic T lymphocytes specific for the prostate specific
CC    polypeptide. The invention is useful for identifying anti-neoplastic
CC    agents. This sequence represents a human prostate specific polypeptide of
```

```
CC    the invention.
XX
SQ    Sequence 843 AA;

  Query Match            100.0%;  Score 40;  DB 10;  Length 843;
  Best Local Similarity   100.0%;  Pred. No. 28;
  Matches     9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 ILILSKIYV 9
             |||||||||
Db       558 ILILSKIYV 566


RESULT 3
AEB13426
ID   AEB13426 standard; protein; 885 AA.
XX
AC   AEB13426;
XX
DT   22-SEP-2005  (first entry)
XX
DE   Human prostate specific polypeptide #2.
XX
KW   Screening; diagnosis; drug delivery; prostate specific polypeptide;
KW   cancer; prostate tumor; cytostatic; neoplasm.
XX
OS   Homo sapiens.
XX
PN   WO2005062788-A2.
XX
PD   14-JUL-2005.
XX
PF   16-DEC-2004; 2004WO-US042406.
XX
PR   22-DEC-2003; 2003US-0531809P.
XX
PA   (AVAL-) AVALON PHARM INC.
XX
PI   Weigle B,  Ebner R;
XX
DR   WPI; 2005-497793/50.
DR   N-PSDB; AEB13425.
XX
PT   Novel isolated prostate specific polypeptide, useful for treating cancer,
PT   and identifying agent that modulates activity of cancer related gene.
XX
PS   Claim 12; SEQ ID NO 5; 59pp; English.
XX
CC   The invention relates to an isolated prostate specific polypeptide
```

```
CC     comprising one or more immunogenic fragments. The invention also relates
CC     to a method of identifying an agent that modulates the activity of a
CC     cancer related gene involving contacting a compound with a cell
CC     containing a gene under conditions promoting the expression of the gene,
CC     detecting a difference in expression of the gene relative to when the
CC     compound is not present and identifying an agent that modulates the
CC     activity of a cancer related gene, a method of identifying an anti-
CC     neoplastic agent involving contacting a cell exhibiting neoplastic
CC     activity with a compound first identified as a cancer related gene
CC     modulator using and determining a decrease in neoplastic activity after
CC     contacting, when compared to when the contacting does not occur, or
CC     administering an agent first identified to an animal exhibiting a cancer
CC     condition and detecting a decrease in cancerous condition, a method of
CC     determining the cancerous status of a cell involving determining an
CC     increase in the level of expression in a cell of a gene where an elevated
CC     expression relative to a known non-cancerous cell indicates a cancerous
CC     state or potentially cancerous state, an antibody that reacts with a
CC     prostate specific polypeptide, an immunoconjugate comprising the antibody
CC     and a cytotoxic agent, a method of treating cancer involving contacting a
CC     cancerous cell in vivo with an agent having activity against a prostate
CC     specific polypeptide and an immunogenic composition the prostate specific
CC     polypeptide. The prostate specific polypeptide is useful for identifying
CC     an agent that modulates the activity of a cancer related gene. The
CC     immunogenic composition is useful for treating cancer, preferably
CC     prostate cancer in an animal, e.g. human, which involves administering
CC     the immunogenic composition that is sufficient to elicit the production
CC     of cytotoxic T lymphocytes specific for the prostate specific
CC     polypeptide. The invention is useful for identifying anti-neoplastic
CC     agents. This sequence represents a human prostate specific polypeptide of
CC     the invention.
XX
SQ     Sequence 885 AA;

    Query Match                100.0%;  Score 40;  DB 10;  Length 885;
    Best Local Similarity      100.0%;  Pred. No. 30;
    Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 ILILSKIYV 9
            |||||||||
Db      558 ILILSKIYV 566


RESULT 4
ABG15488
ID   ABG15488 standard; protein; 898 AA.
XX
AC   ABG15488;
XX
DT   18-FEB-2002  (first entry)
```

```
XX
DE    Novel human diagnostic protein #15479.
XX
KW    Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW    food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS    Homo sapiens.
XX
PN    WO200175067-A2.
XX
PD    11-OCT-2001.
XX
PF    30-MAR-2001; 2001WO-US008631.
XX
PR    31-MAR-2000; 2000US-00540217.
PR    23-AUG-2000; 2000US-00649167.
XX
PA    (HYSE-) HYSEQ INC.
XX
PI    Drmanac RT, Liu C, Tang YT;
XX
DR    WPI; 2001-639362/73.
DR    N-PSDB; AAS79675.
XX
PT    New isolated polynucleotide and encoded polypeptides, useful in
PT    diagnostics, forensics, gene mapping, identification of mutations
PT    responsible for genetic disorders or other traits and to assess
PT    biodiversity.
XX
PS    Claim 20; SEQ ID NO 45847; 103pp; English.
XX
CC    The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC    sequences. (I) is useful as hybridisation probes, polymerase chain
CC    reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC    and in recombinant production of (II). The polynucleotides are also used
CC    in diagnostics as expressed sequence tags for identifying expressed
CC    genes. (I) is useful in gene therapy techniques to restore normal
CC    activity of (II) or to treat disease states involving (II). (II) is
CC    useful for generating antibodies against it, detecting or quantitating a
CC    polypeptide in tissue, as molecular weight markers and as a food
CC    supplement. (II) and its binding partners are useful in medical imaging
CC    of sites expressing (II). (I) and (II) are useful for treating disorders
CC    involving aberrant protein expression or biological activity. The
CC    polypeptide and polynucleotide sequences have applications in
CC    diagnostics, forensics, gene mapping, identification of mutations
CC    responsible for genetic disorders or other traits to assess biodiversity
CC    and to produce other types of data and products dependent on DNA and
CC    amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC    amino acid sequences of the invention. Note: The sequence data for this
```

```
CC    patent did not appear in the printed specification, but was obtained in
CC    electronic format directly from WIPO at
CC    ftp.wipo.int/pub/published_pct_sequences
XX
SQ    Sequence 898 AA;

   Query Match              100.0%;  Score 40;  DB 4;  Length 898;
   Best Local Similarity    100.0%;  Pred. No. 30;
   Matches     9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;


Qy         1 ILILSKIYV 9
             |||||||||
Db       654 ILILSKIYV 662


RESULT 5
ADT77664
ID   ADT77664 standard; protein; 933 AA.
XX
AC   ADT77664;
XX
DT   15-JUN-2007  (revised)
DT   13-JAN-2005  (first entry)
XX
DE   Splice variant-novel gene expressed in prostate (SV-NGEP) polypeptide.
XX
KW   Splice variant-novel gene expressed in prostate; SV-NGEP; human;
KW   prostate cancer; cytostatic; gene therapy; immunotherapy; BOND_PC;
KW   NGEP long variant; NGEP long variant [Homo sapiens]; GO5886.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          1. .345
FT                   /label= Cytoplasmic
FT   Region          157. .933
FT                   /note= "An immunogenic fragment comprising 8 consecutive
FT                   amino acids that specifically binds to an antibody that
FT                   specifixally binds to a polypeptide comprising amino
FT                   acids 157-933 is referred to in Claim 1"
FT   Region          170. .178
FT                   /note= "Epitope, predicted to bind HLA2-01"
FT   Region          215. .223
FT                   /note= "Epitope, predicted to bind HLA2-01"
FT   Region          258. .266
FT                   /note= "Epitope, predicted to bind HLA2-01"
FT   Domain          346. .368
FT                   /label= Transmembrane
FT   Domain          369. .421
```

```
FT                      /label= External
FT                      /note= "Cell surface"
FT      Region          403. .411
FT                      /note= "Epitope, predicted to bind HLA2-01"
FT      Domain          422. .441
FT                      /label= Transmembrane
FT      Region          427. .435
FT                      /note= "Epitope, predicted to bind HLA2-01"
FT      Domain          442. .501
FT                      /label= Cytoplasmic
FT      Domain          502. .524
FT                      /label= Transmembrane
FT      Domain          525. .543
FT                      /label= External
FT                      /note= "Cell surface"
FT      Domain          544. .566
FT                      /label= Transmembrane
FT      Region          557. .565
FT                      /note= "Epitope, predicted to bind HLA2-01"
FT      Region          562. .570
FT                      /note= "Epitope, predicted to bind HLA2-01"
FT      Domain          567. .586
FT                      /label= Cytoplasmic
FT      Domain          587. .609
FT                      /label= Transmembrane
FT      Domain          610. .714
FT                      /label= External
FT                      /note= "Cell surface"
FT      Domain          715. .737
FT                      /label= Transmembrane
FT      Domain          738. .761
FT                      /label= Cytoplasmic
FT      Domain          762. .784
FT                      /label= Transmembrane
FT      Domain          785. .933
FT                      /label= External
FT                      /note= "Cell surface"
FT      Region          846. .854
FT                      /note= "Epitope, predicted to bind HLA2-01"
XX
PN      WO2004092213-A1.
XX
PD      28-OCT-2004.
XX
PF      05-APR-2004; 2004WO-US010588.
XX
PR      08-APR-2003; 2003US-0461399P.
XX
PA      (USSH ) US DEPT HEALTH & HUMAN SERVICES.
```

```
XX
PI    Pastan I,  Bera TK,  Lee B;
XX
DR    WPI; 2004-758338/74.
DR    N-PSDB; ADT77665.
DR    PC:NCBI; gi48093524.
XX
PT    New Splice Variant-Novel Gene Expressed in Prostate polypeptide or
PT    encoding nucleic acid molecule for diagnosing, preventing or treating
PT    cancer, especially prostate cancer.
XX
PS    Claim 1; SEQ ID NO 1; 88pp; English.
XX
CC    The present sequence is the protein sequence of splice variant-novel gene
CC    expressed in prostate (SV-NGEP). SV-NGEP is identical to NGEP from amino
CC    acid 1-157, diverging from amino acid 158. Expression analysis in 76
CC    normal and foetal tissues showed SV-NGEP to be strongly expressed only in
CC    a prostate sample. Claimed methods for detecting prostate cancer in a
CC    subject comprise: contacting the sample with an antibody that
CC    specifically binds a SV-NGEP polypeptide and detecting the formation of
CC    an immune complex; or detecting an increase in expression of SV-NGEP
CC    polypeptide or mRNA. Antibodies to an SV-NGEP polypeptide can be used to
CC    detect metastatic prostate cancer cells at locations other than the
CC    prostate. A claimed method for producing an immune response against a
CC    cell expressing SV-NGEP, for example in a subject with prostate cancer,
CC    comprises administering the polypeptide, or a polynucleotide encoding it,
CC    to produce an immune response that decreases growth of the prostate
CC    cancer. A claimed method for inhibiting the growth of a malignant cell
CC    that expresses SV-NGEP comprises culturing cytotoxic T lymphocytes (CTLs)
CC    with SV-NGEP to produce activated CTLs that recognise an NGEP expressing
CC    cell, and contacting the malignant cell with the activated CTLs.
CC    Alternatively, growth of a malignant cell is inhibited by contact with an
CC    antibody that specifically binds an SV-NGEP polypeptide, where the
CC    antibody is linked to an effector molecule (chemotherapeutic agent or
CC    toxin) that inhibits growth of the malignant cell. This may be performed
CC    in vivo. Kits for detecting an SV-NGEP polypeptide or polynucleotide in a
CC    sample are also claimed.
CC
CC    Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC    information from BOND.
XX
SQ    Sequence 933 AA;

    Query Match            100.0%;  Score 40;  DB 8;  Length 933;
    Best Local Similarity  100.0%;  Pred. No. 31;
    Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 ILILSKIYV 9
           |||||||||
```

```
Db         557 ILILSKIYV 565
```

```
RESULT 6
AEL84788
ID   AEL84788 standard; protein; 933 AA.
XX
AC   AEL84788;
XX
DT   18-OCT-2007  (revised)
DT   15-JUN-2007  (revised)
DT   28-DEC-2006  (first entry)
XX
DE   Tumor marker gene NGEP SEQ ID NO 155.
XX
KW   cytostatic; diagnosis; prognosis; tumor marker; gene expression;
KW   drug screening; cancer; neoplasm; NGEP; BOND_PC; NGEP long variant;
KW   G05886.
XX
OS   Homo sapiens.
XX
PN   WO2006110593-A2.
XX
PD   19-OCT-2006.
XX
PF   07-APR-2006; 2006WO-US013172.
XX
PR   07-APR-2005; 2005US-0669342P.
PR   11-OCT-2005; 2005US-0725982P.
XX
PA   (MACR-) MACROGENICS INC.
XX
PI   Von Haller PD,  Schummer M,  Meyer DW,  Schubert LA,  Tjoelker LW;
XX
DR   WPI; 2006-814687/82.
DR   N-PSDB; AEL84787.
DR   REFSEQ; NP_001001891.
DR   PC:NCBI; gi48093524.
XX
PT   Detecting or diagnosing cancer in a subject comprises determining
PT   expression of at least one gene, and comparing level of expression to a
PT   control sample from a normal subject, where increased expression level
PT   indicates cancer.
XX
PS   Claim 8; SEQ ID NO 155; 583pp; English.
XX
CC   The invention describes a method of detecting or diagnosing cancer in a
CC   subject comprising determining the expression level of at least one gene,
CC   and comparing the level of expression to a corresponding control sample
```

```
CC    from a normal subject, where cancer is detected or diagnosed if there is
CC    an increase in the expression level of the gene relative to the
CC    expression in the control sample. Also described are: identifying a
CC    compound to be tested for its ability to prevent, treat, manage, or
CC    ameliorate cancer or its symptom; a compound identified by the method;
CC    treating cancer in a patient; treating a cancer in a subject that is
CC    fully or partially refractory to a first treatment in a patient; and a
CC    pharmaceutical composition comprising an amount of an antibody selected
CC    from anti-SLC12A2, anti-FLJ23375, anti-GRM5, anti-TAS2R1, anti-NRXN2,
CC    anti-C14orf160, anti-MGC 15668, anti-MGC33486, anti-TMEM16F, anti-FAT,
CC    anti-KIAA0195, anti-LRFN, anti-NFASC, anti-BAT2D1, anti-MGC2963, anti-
CC    KIAA0685, anti-EDG3, anti-GGTL3, anti-PLVAP, anti-FLJ31528, anti-
CC    FLJ90709, anti-VEZATIN, anti-TMPRSS9, anti-ATP13A5, anti-PKHD1L1, anti-
CC    C2orf18, anti-ANKRD22, anti-FAM62B, anti-LOC57168, anti-CDKAL1, anti-
CC    SLC39A3v1, anti-SLC39A3v2, anti-BAT5, anti-TM9SF4, anti-DC2, anti-VAPB,
CC    anti-XTP3TPB, anti-TACSTD2, anti-FNDC3A, anti-GK001, anti-OCIAD2, anti-
CC    PRO1855, anti-C20orf3, anti-SDFR1, anti-FLJ20481, anti-LENG4, anti-
CC    FLJ12443, anti-ARP5 Long, anti-ARP5 Short, anti-TMD0645, anti-NGEP, anti-
CC    IL1RAP1, anti-PLXNB1, anti-ATP2B2, anti~FLJ11848, anti-ENTPD2, anti-
CC    PPM1H, anti-KRTKAP3, anti-KCNC3, anti-TM9SF1, anti-ULBP1, anti-C19orf26,
CC    anti-KIAA830, anti-KIAA1244, anti-KIAA1797, anti-MGC26856, anti-NETO2,
CC    anti-SUSD2, anti-FOLR2, anti-EMR2, ENTPD1, anti-ATP10B, anti-PTK7, anti-
CC    FLJ14681, anti-C20orf22, anti-FLJ14281, anti-FAM8Al, anti-TMED7, anti-
CC    C20orf108, anti-ATAD1, anti-GPR154, anti-C14orf27, anti-OSAP, anti-
CC    FAD104, anti-FLJ90492, anti-SLC27A3, anti-RON, anti-ATP13A1, anti-
CC    DKFZP564D166, anti-ESSPL, anti-EXTL3, anti-KAI1, anti-KIAA0960, anti-
CC    MTRNL, anti-SLC27A1, anti-GRIA, anti-OR4M1, anti-KIAA1679, or anti-UPK-1b
CC    antibody, and a pharmaceutical carrier. The methods are useful for
CC    detecting, diagnosing, and treating cancer, e.g. colon, lung, ovary,
CC    prostate, pancreas, or bladder cancer. This is the amino acid sequence of
CC    NGEP, altered levels of expression are useful in the diagnosis or
CC    prognosis of cancer.
CC
CC    Revised record issued on 18-OCT-2007 : Enhanced with precomputed
CC    information from BOND.
XX
SQ    Sequence 933 AA;

   Query Match            100.0%;  Score 40;  DB 11;  Length 933;
   Best Local Similarity  100.0%;  Pred. No. 31;
   Matches   9;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 ILILSKIYV 9
          |||||||||
Db    557 ILILSKIYV 565


RESULT 7
AFP84242
```

```
ID    AFP84242 standard; protein; 67 AA.
XX
AC    AFP84242;
XX
DT    18-OCT-2007  (first entry)
XX
DE    Glycine max protein SEQ ID NO:175420.
XX
KW    plant; cold tolerance; heat tolerance; drought resistance;
KW    herbicide resistance; pathogen resistance; pesticide resistance;
KW    disease-resistance; crop improvement; insect resistance;
KW    nitrogen fixation; plant growth regulation; plant disease;
KW    stress tolerance; seed oil; transgenic.
XX
OS    Glycine max.
XX
PN    US2004031072-A1.
XX
PD    12-FEB-2004.
XX
PF    28-APR-2003; 2003US-00424599.
XX
PR    06-MAY-1999;   99US-00304517.
PR    05-NOV-2001; 2001US-00985678.
XX
PA    (LROS/) LA ROSA T J.
PA    (ZHOU/) ZHOU Y.
PA    (KOVA/) KOVALIC D K.
PA    (CAOY/) CAO Y.
XX
PI    La Rosa TJ,  Zhou Y,  Kovalic DK,  Cao Y;
XX
DR    WPI; 2004-168999/16.
XX
PT    New recombinant DNA construct, useful in producing plants with desired
PT    properties, e.g. increased cold, heat or drought tolerance or tolerance
PT    to herbicides, extreme osmotic conditions or pathogens and improved plant
PT    growth and development.
XX
PS    Claim 2; SEQ ID NO 175420; 15pp; English.
XX
CC    The invention relates to a recombinant DNA construct, polynucleotides or
CC    polypeptides which are useful in improving plant cold, heat or drought
CC    tolerance or tolerance to herbicides, extreme osmotic conditions,
CC    pathogens or pests, in improving yield by modification of photosynthesis
CC    or of carbohydrate, nitrogen or phosphorus use and/or uptake, in
CC    manipulating growth rate in plant cells by modification of the cell cycle
CC    pathway, in providing increased resistance to plant disease and improved
CC    plant growth and development under at least one stress condition, in
```

```
CC    producing galactomannan, plant growth regulators and lignin, in
CC    increasing the rate of homologous recombination in plants, in modifying
CC    seed oil yield and/or content and seed protein yield and/or content and
CC    in encoding a plant transcription factor. The present sequence represents
CC    a Glycine max protein of the invention. Note: This sequence is not shown
CC    in the specification but was obtained in electronic format directly from
CC    USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ    Sequence 67 AA;

  Query Match             82.5%;  Score 33;  DB 8;  Length 67;
  Best Local Similarity   66.7%;  Pred. No. 46;
  Matches     6;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 ILILSKIYV 9
             :|||:|:||
Db        53 LLILTKLYV 61


RESULT 8
AER37498
ID    AER37498 standard; protein; 84 AA.
XX
AC    AER37498;
XX
DT    04-OCT-2007  (first entry)
XX
DE    Human secreted protein SEQ ID NO 5602.
XX
KW    Protein secretion; Andrology; Cardiovascular disease; Endocrine disease;
KW    Gastrointestinal disease; Genitourinary disease;
KW    Gynecology and obstetrics; Hematological disease; Immune disorder;
KW    Injury; Musculoskeletal disease; Neoplasm; Neurological disease;
KW    Respiratory disease; vulnerary; uropathic; respiratory-gen.; osteopathic;
KW    neuroprotective; muscular-gen.; immunomodulator; gynecological;
KW    gastrointestinal-gen.; endocrine-gen.; cytostatic; cardiovascular-gen.;
KW    antiinfertility; antianemic; gene therapy.
XX
OS    Homo sapiens.
XX
PN    US2007015271-A1.
XX
PD    18-JAN-2007.
XX
PF    02-APR-2003; 2003US-00405027.
XX
PR    04-APR-2002; 2002US-0369608P.
PR    30-APR-2002; 2002US-0376175P.
XX
```

```
PA    (ROSE/)  ROSEN C A.
PA    (RUBE/)  RUBEN S M.
XX
PI    Rosen CA,   Ruben SM;
XX
DR    WPI; 2007-252440/25.
DR    N-PSDB; AER34598.
XX
PT    New polypeptide, nucleic acid, antibody or its fragment, or an agonist or
PT    antagonist, useful for preparing a composition in diagnosing or treating
PT    a medical condition, e.g. neoplastic, cardiovascular or gastrointestinal
PT    disorders.
XX
PS    Claim 13; SEQ ID NO 5602; 277pp; English.
XX
CC    The invention relates to a polypeptide comprising an amino acid sequence
CC    that is at least 95% identical to a sequence given in the specification.
CC    The invention includes: a method of using the polypeptide, nucleic acid,
CC    antibody or its fragment, or an agonist or antagonist for preparing a
CC    composition for diagnosing or treating a medical condition; a method of
CC    using the polypeptide for identifying a binding partner; a recombinant
CC    vector comprising the nucleic acid molecule; and a recombinant host cell
CC    comprising the vector. The polypeptide, nucleic acid, antibody or its
CC    fragment, or an agonist or antagonist is useful for preparing a
CC    composition for diagnosing or treating a medical condition, e.g.,
CC    andrology, cardiovascular disease, endocrine disease, gastrointestinal
CC    disease, genitourinary disease, gynecology and obstetrics, hematological
CC    disease, immune disorder, injury, musculoskeletal disease, neoplasm,
CC    neurological disease, respiratory disease. The present sequence is that
CC    of a secreted protein of the invention. Note: The sequence data for this
CC    patent did not form part of the printed specification, but was obtained
CC    in electronic format directly from WIPO at
CC    ftp.wipo.int/pub/published_pct_sequences.
XX
SQ    Sequence 84 AA;

   Query Match                80.0%;  Score 32;  DB 12;  Length 84;
   Best Local Similarity      77.8%;  Pred. No. 97;
   Matches    7;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         1 ILILSKIYV 9
             |||| |:||
Db        56 ILILFKLYV 64


RESULT 9
ABB53430
ID    ABB53430 standard; protein; 117 AA.
XX
```

```
AC    ABB53430;
XX
DT    29-AUG-2003  (revised)
DT    16-MAY-2002  (first entry)
XX
DE    Lactococcus lactis protein rnpA.
XX
KW    Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.
XX
OS    Lactococcus lactis; IL1403.
XX
PN    FR2807446-A1.
XX
PD    12-OCT-2001.
XX
PF    11-APR-2000; 2000FR-00004630.
XX
PR    11-APR-2000; 2000FR-00004630.
XX
PA    (INRG ) INRA INST NAT RECH AGRONOMIQUE.
XX
PI    Bolotine A,  Sorokine A,  Renault P,  Ehrlich SD;
XX
DR    WPI; 2002-043418/06.
XX
PT    New nucleotide sequence useful in the identification or Lactococcus
PT    lactis and related species.
XX
PS    Claim 6; SEQ ID NO 132; 2504pp; French.
XX
CC    The present invention is related to a Lactococcus lactis nucleotide
CC    sequence (ABA90521) and related proteins (ABB53300-ABB55621). The nucleic
CC    acid sequence is useful in the detection and/or amplification of nucleic
CC    acid sequence, particularly to identify Lactococcus lactis or related
CC    species. The proteins of the invention are useful for the biosynthesis or
CC    biodegradation of a composition of interest. The invention helps research
CC    in lactic bacteria, particularly useful in the production of yogurt and
CC    cheese. Note: The sequence data for this patent is based on equivalent
CC    patent WO200177334 (published 18-OCT-2001) which is available in
CC    electronic format directly from WIPO at
CC    ftp.wipo.int/pub/published_pct_sequences. (Updated on 29-AUG-2003 to
CC    standardise OS field)
XX
SQ    Sequence 117 AA;

  Query Match              80.0%;  Score 32;  DB 5;  Length 117;
  Best Local Similarity    77.8%;  Pred. No. 1.4e+02;
  Matches    7;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          1 ILILSKIYV 9
            :| ||||||
Db        104 VLKLSKIYV 112


RESULT 10
AAU19199
ID   AAU19199 standard; protein; 199 AA.
XX
AC   AAU19199;
XX
DT   04-DEC-2001  (first entry)
XX
DE   Human G protein-coupled receptor nGPCR-2396.
XX
KW   Human; G protein-coupled receptor; nGPCR-x; antiviral; analgesic;
KW   cytostatic; cardiant; antidiabetic; anoretic; hypotensive; hypertensive;
KW   antiparkinsonian; nootropic; neuroprotective; antidepressant;
KW   viral infection; HIV-1; human immunodeficiency virus; HIV-2; pain;
KW   cancer; metabolic disease; cardiovascular disease; type 2 diabetes;
KW   obesity; anorexia; hypotension; hypertension; myocardial infarction;
KW   atherosclerosis; Parkinson's disease; psychosis; neurological disorder;
KW   schizophrenia; migraine; major depression; anxiety; mental disorder;
KW   manic depression; dyskinesia; Huntington's disease; Tourette's Syndrome.
XX
OS   Homo sapiens.
XX
PN   WO200166750-A2.
XX
PD   13-SEP-2001.
XX
PF   08-MAR-2001; 2001WO-US007322.
XX
PR   08-MAR-2000; 2000US-0187581P.
PR   08-MAR-2000; 2000US-0187582P.
PR   08-MAR-2000; 2000US-0187714P.
PR   08-MAR-2000; 2000US-0187715P.
PR   08-MAR-2000; 2000US-0187825P.
PR   08-MAR-2000; 2000US-0187828P.
PR   08-MAR-2000; 2000US-0187829P.
PR   08-MAR-2000; 2000US-0187830P.
PR   08-MAR-2000; 2000US-0187833P.
PR   08-MAR-2000; 2000US-0187874P.
PR   08-MAR-2000; 2000US-0187928P.
PR   08-MAR-2000; 2000US-0187929P.
PR   08-MAR-2000; 2000US-0187930P.
PR   08-MAR-2000; 2000US-0188049P.
PR   08-MAR-2000; 2000US-0189294P.
XX
```

```
PA    (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI    Vogeli G,  Wood LS;
XX
DR    WPI; 2001-536778/59.
DR    N-PSDB; AAS30768.
XX
PT    Isolated nucleic acid molecules encoding G protein-coupled receptors
PT    termed nGPCR-x, useful in the treatment and diagnosis of viral
PT    infections, cancers and mental disorders (e.g. Parkinson's disease and
PT    schizophrenia).
XX
PS    Claim 31; Page 266; 336pp; English.
XX
CC    The invention relates to novel isolated nucleic acid molecules encoding G
CC    protein-coupled receptors termed nGPCR-x. nGPCR-x polynucleotides,
CC    polypeptides, and modulators may be used in the treatment of diseases and
CC    conditions such as infections, such as viral infections caused by HIV-1
CC    (human immunodeficiency virus) or HIV-2, pain, cancers, metabolic and
CC    cardiovascular diseases and disorders (e.g., type 2 diabetes, obesity,
CC    anorexia, hypotension, hypertension, myocardial infarction,
CC    atherosclerosis), Parkinson's disease, and psychotic and neurological
CC    disorders, including schizophrenia, migraine, major depression, anxiety,
CC    mental disorder, manic depression, and dyskinesias, such as Huntington's
CC    disease or Tourette's Syndrome and many other diseases and syndromes
CC    listed in the specification. nGPCR-x polynucleotides and polypeptides, as
CC    well as nGPCR-x modulators, may also be used in diagnostic assays for
CC    such diseases or conditions. The present sequence represents a G protein-
CC    coupled receptor of the invention
XX
SQ    Sequence 199 AA;

  Query Match              80.0%;  Score 32;  DB 4;  Length 199;
  Best Local Similarity    66.7%;  Pred. No. 2.6e+02;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1 ILILSKIYV 9
            ||| :|||:
Db       16 ILIFNKIYI 24


RESULT 11
ABG29976
ID    ABG29976 standard; protein; 293 AA.
XX
AC    ABG29976;
XX
DT    18-FEB-2002  (first entry)
XX
```

```
DE      Novel human diagnostic protein #29967.
XX
KW      Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW      food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS      Homo sapiens.
XX
PN      WO200175067-A2.
XX
PD      11-OCT-2001.
XX
PF      30-MAR-2001; 2001WO-US008631.
XX
PR      31-MAR-2000; 2000US-00540217.
PR      23-AUG-2000; 2000US-00649167.
XX
PA      (HYSE-) HYSEQ INC.
XX
PI      Drmanac RT,  Liu C,  Tang YT;
XX
DR      WPI; 2001-639362/73.
DR      N-PSDB; AAS94163.
XX
PT      New isolated polynucleotide and encoded polypeptides, useful in
PT      diagnostics, forensics, gene mapping, identification of mutations
PT      responsible for genetic disorders or other traits and to assess
PT      biodiversity.
XX
PS      Claim 20; SEQ ID NO 60335; 103pp; English.
XX
CC      The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC      sequences. (I) is useful as hybridisation probes, polymerase chain
CC      reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC      and in recombinant production of (II). The polynucleotides are also used
CC      in diagnostics as expressed sequence tags for identifying expressed
CC      genes. (I) is useful in gene therapy techniques to restore normal
CC      activity of (II) or to treat disease states involving (II). (II) is
CC      useful for generating antibodies against it, detecting or quantitating a
CC      polypeptide in tissue, as molecular weight markers and as a food
CC      supplement. (II) and its binding partners are useful in medical imaging
CC      of sites expressing (II). (I) and (II) are useful for treating disorders
CC      involving aberrant protein expression or biological activity. The
CC      polypeptide and polynucleotide sequences have applications in
CC      diagnostics, forensics, gene mapping, identification of mutations
CC      responsible for genetic disorders or other traits to assess biodiversity
CC      and to produce other types of data and products dependent on DNA and
CC      amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC      amino acid sequences of the invention. Note: The sequence data for this
CC      patent did not appear in the printed specification, but was obtained in
```

```
CC    electronic format directly from WIPO at
CC    ftp.wipo.int/pub/published_pct_sequences
XX
SQ    Sequence 293 AA;

   Query Match               80.0%;  Score 32;  DB 4;  Length 293;
   Best Local Similarity    66.7%;  Pred. No. 4.1e+02;
   Matches      6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 ILILSKIYV 9
              :|:|  ||||
Db        265 LLLLDKIYV 273


RESULT 12
AET18366
ID    AET18366 standard; protein; 366 AA.
XX
AC    AET18366;
XX
DT    17-MAY-2007  (first entry)
XX
DE    C. albicans pathological condition related protein SEQ ID NO:17343.
XX
KW    diagnosis; fungal infection; biological control agent; therapeutic;
KW    candida albicans infection; fungicide; vaccine.
XX
OS    Candida albicans.
XX
PN    US6747137-B1.
XX
PD    08-JUN-2004.
XX
PF    12-FEB-1999;   99US-00248796.
XX
PR    13-FEB-1998;   98US-0074725P.
PR    13-AUG-1998;   98US-0096409P.
XX
PA    (GENO-) GENOME THERAPEUTICS CORP.
XX
PI    Weinstock KG,  Bush D;
XX
DR    WPI; 2004-429806/40.
DR    N-PSDB; AET04263.
XX
PT    New nucleic acids and encoded polypeptides derived from Candida albicans,
PT    useful for diagnosing, preventing and/or treating pathological conditions
PT    resulting from fungal infections, and as biocontrol agents for plants.
XX
```

```
PS    Disclosure; SEQ ID NO 17343; 872pp; English.
XX
CC    The invention relates to an isolated nucleic acid comprising a nucleotide
CC    sequence encoding a Candida albicans polypeptide. Also disclosed is a
CC    recombinant expression vector comprising a Candida albicans polypeptide
CC    nucleotide sequence, a cell comprising the recombinant expression vector,
CC    a probe comprising a fragment of the nucleotide sequence, an isolated
CC    nucleic acid comprising 50 or more consecutive nucleotides from the
CC    nucleotide sequences cited above and encoding a C. albicans polypeptide
CC    and a probe consisting essentially of any of the nucleotide sequences
CC    cited above. Also disclosed are polypeptides, antibodies and methods of
CC    producing the compositions of the present invention. The methods and
CC    compositions of the present invention are useful for the diagnosis,
CC    prevention and/or treatment of pathological conditions resulting from
CC    fungal infections, and as biocontrol agents for plants. The present
CC    sequence represents the amino acid sequence of a C. albicans pathological
CC    condition related protein.
XX
SQ    Sequence 366 AA;

   Query Match            80.0%;  Score 32;  DB 8;  Length 366;
   Best Local Similarity  75.0%;  Pred. No. 5.3e+02;
   Matches     6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 ILILSKIY 8
             |:||||:|
Db       104 IVILSKVY 111


RESULT 13
ADR09066
ID    ADR09066 standard; protein; 596 AA.
XX
AC    ADR09066;
XX
DT    15-JUN-2007  (revised)
DT    04-NOV-2004  (first entry)
XX
DE    Human protein useful for treating neurological disease Seq 2572.
XX
KW    human; oligo-capping method; diagnostic marker; gene therapy;
KW    osteoporosis; neurological disease; Alzheimer's disease;
KW    Parkinson's disease; dementia; short memory; cancer;
KW    sense or motor function; emotional reaction; fear response; panic;
KW    osteopathic; neuroprotective; nootropic; antiparkinsonian; cytostatic;
KW    tranquiliser; BOND_PC; unnamed protein product;
KW    unnamed protein product [Homo sapiens]; GO5488.
XX
OS    Homo sapiens.
```

```
XX
PN    EP1447413-A2.
XX
PD    18-AUG-2004.
XX
PF    12-FEB-2004; 2004EP-00003145.
XX
PR    14-FEB-2003; 2003JP-00102207.
PR    09-MAY-2003; 2003JP-00131452.
XX
PA    (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI    Isogai T,  Yamamoto J,  Nishikawa T,  Isono Y,  Sugiyama T,  Otsuki T;
PI    Wakamatsu A,  Ishii S,  Nagai K,  Irie R;
XX
DR    WPI; 2004-583265/57.
DR    N-PSDB; ADR07110.
DR    PC:NCBI; gi34534079.
DR    PC:SWISSPROT; Q8TF17.
XX
PT    New 1995 cDNA, useful for treating osteoporosis, neurological diseases,
PT    Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX
PS    Claim 1; SEQ ID NO 2572; 2686pp; English.
XX
CC    This invention relates to novel, isolated full length human cDNA
CC    molecules and the encoded proteins thereof. Specifically, it refers to
CC    cDNA clones obtained by an oligo-capping method, where none of these
CC    clones are identical to any known human mRNAs. The present invention
CC    describes an immunoassay to identify agonists and antagonists, as well as
CC    antibodies, antisense molecules and siRNAs that can all be used to bind
CC    to and modulate expression of the cDNA molecules. As such, these
CC    molecules are useful for diagnostic markers or therapeutic targets for
CC    the various diseases or morbid states. In particular, they are useful in
CC    gene therapy for treating osteoporosis, neurological disease, Alzheimer's
CC    disease, Parkinson's disease, dementia, short memory and various cancers,
CC    as well as for maintaining equilibrium of sense or motor function, and
CC    for treating emotional reaction, fear response and panic. Accordingly,
CC    they exhibit osteopathic, neuroprotective, nootropic, antiparkinsonian,
CC    cytostatic and tranquiliser activities. This polypeptide is a protein
CC    encoded by a full length human cDNA sequence of the invention. NOTE: This
CC    sequence is not given in the sequence listing of the specification but
CC    can be obtained on CD-ROM from the European Patent Office, Vienna Sub-
CC    office.
CC
CC    Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC    information from BOND.
XX
SQ    Sequence 596 AA;
```

```
   Query Match            80.0%;  Score 32;  DB 8;  Length 596;
   Best Local Similarity  75.0%;  Pred. No. 9.3e+02;
   Matches    6;  Conservative    2;  Mismatches   0;  Indels   0;  Gaps    0;

Qy         2 LILSKIYV 9
             |||||:|:
Db       308 LILSKVYL 315
```

RESULT 14
ADR09060
ID   ADR09060 standard; protein; 726 AA.
XX
AC   ADR09060;
XX
DT   04-NOV-2004 (first entry)
XX
DE   Human protein useful for treating neurological disease Seq 2566.
XX
KW   human; oligo-capping method; diagnostic marker; gene therapy;
KW   osteoporosis; neurological disease; Alzheimer's disease;
KW   Parkinson's disease; dementia; short memory; cancer;
KW   sense or motor function; emotional reaction; fear response; panic;
KW   osteopathic; neuroprotective; nootropic; antiparkinsonian; cytostatic;
KW   tranquiliser.
XX
OS   Homo sapiens.
XX
PN   EP1447413-A2.
XX
PD   18-AUG-2004.
XX
PF   12-FEB-2004; 2004EP-00003145.
XX
PR   14-FEB-2003; 2003JP-00102207.
PR   09-MAY-2003; 2003JP-00131452.
XX
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI   Isogai T, Yamamoto J, Nishikawa T, Isono Y, Sugiyama T, Otsuki T;
PI   Wakamatsu A, Ishii S, Nagai K, Irie R;
XX
DR   WPI; 2004-583265/57.
DR   N-PSDB; ADR07104.
XX
PT   New 1995 cDNA, useful for treating osteoporosis, neurological diseases,
PT   Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX

```
PS     Claim 1; SEQ ID NO 2566; 2686pp; English.
XX
CC     This invention relates to novel, isolated full length human cDNA
CC     molecules and the encoded proteins thereof. Specifically, it refers to
CC     cDNA clones obtained by an oligo-capping method, where none of these
CC     clones are identical to any known human mRNAs. The present invention
CC     describes an immunoassay to identify agonists and antagonists, as well as
CC     antibodies, antisense molecules and siRNAs that can all be used to bind
CC     to and modulate expression of the cDNA molecules. As such, these
CC     molecules are useful for diagnostic markers or therapeutic targets for
CC     the various diseases or morbid states. In particular, they are useful in
CC     gene therapy for treating osteoporosis, neurological disease, Alzheimer's
CC     disease, Parkinson's disease, dementia, short memory and various cancers,
CC     as well as for maintaining equilibrium of sense or motor function, and
CC     for treating emotional reaction, fear response and panic. Accordingly,
CC     they exhibit osteopathic, neuroprotective, nootropic, antiparkinsonian,
CC     cytostatic and tranquiliser activities. This polypeptide is a protein
CC     encoded by a full length human cDNA sequence of the invention. NOTE: This
CC     sequence is not given in the sequence listing of the specification but
CC     can be obtained on CD-ROM from the European Patent Office, Vienna Sub-
CC     office.
XX
SQ     Sequence 726 AA;

   Query Match             80.0%;  Score 32;  DB 8;  Length 726;
   Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
   Matches     6;  Conservative   2;  Mismatches   0;  Indels   0;  Gaps   0;


Qy        2 LILSKIYV 9
            ||||:|:
Db      308 LILSKVYL 315


RESULT 15
ADR09928
ID   ADR09928 standard; protein; 766 AA.
XX
AC   ADR09928;
XX
DT   04-NOV-2004  (first entry)
XX
DE   Human protein useful for treating neurological disease Seq 3434.
XX
KW   human; oligo-capping method; diagnostic marker; gene therapy;
KW   osteoporosis; neurological disease; Alzheimer's disease;
KW   Parkinson's disease; dementia; short memory; cancer;
KW   sense or motor function; emotional reaction; fear response; panic;
KW   osteopathic; neuroprotective; nootropic; antiparkinsonian; cytostatic;
KW   tranquiliser.
```

```
XX
OS    Homo sapiens.
XX
PN    EP1447413-A2.
XX
PD    18-AUG-2004.
XX
PF    12-FEB-2004; 2004EP-00003145.
XX
PR    14-FEB-2003; 2003JP-00102207.
PR    09-MAY-2003; 2003JP-00131452.
XX
PA    (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI    Isogai T,  Yamamoto J,  Nishikawa T,  Isono Y,  Sugiyama T,  Otsuki T;
PI    Wakamatsu A,  Ishii S,  Nagai K,  Irie R;
XX
DR    WPI; 2004-583265/57.
DR    N-PSDB; ADR07972.
XX
PT    New 1995 cDNA, useful for treating osteoporosis, neurological diseases,
PT    Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX
PS    Claim 1; SEQ ID NO 3434; 2686pp; English.
XX
CC    This invention relates to novel, isolated full length human cDNA
CC    molecules and the encoded proteins thereof. Specifically, it refers to
CC    cDNA clones obtained by an oligo-capping method, where none of these
CC    clones are identical to any known human mRNAs. The present invention
CC    describes an immunoassay to identify agonists and antagonists, as well as
CC    antibodies, antisense molecules and siRNAs that can all be used to bind
CC    to and modulate expression of the cDNA molecules. As such, these
CC    molecules are useful for diagnostic markers or therapeutic targets for
CC    the various diseases or morbid states. In particular, they are useful in
CC    gene therapy for treating osteoporosis, neurological disease, Alzheimer's
CC    disease, Parkinson's disease, dementia, short memory and various cancers,
CC    as well as for maintaining equilibrium of sense or motor function, and
CC    for treating emotional reaction, fear response and panic. Accordingly,
CC    they exhibit osteopathic, neuroprotective, nootropic, antiparkinsonian,
CC    cytostatic and tranquiliser activities. This polypeptide is a protein
CC    encoded by a full length human cDNA sequence of the invention. NOTE: This
CC    sequence is not given in the sequence listing of the specification but
CC    can be obtained on CD-ROM from the European Patent Office, Vienna Sub-
CC    office.
XX
SQ    Sequence 766 AA;

      Query Match          80.0%;  Score 32;  DB 8;  Length 766;
      Best Local Similarity  75.0%;  Pred. No. 1.2e+03;
```

```
   Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 LILSKIYV 9
              |||||:|:
Db        239 LILSKVYL 246


Search completed: June 30, 2008, 17:52:59
Job time : 74.875 secs
```

SCORE 3.0